Many thanks to our generous sponsors.
Cell Medica is a leading cellular therapeutics company in the field of personalised T-cell immunotherapies for the treatment of cancer and infections.
Cell Medica’s lead cell therapy is CMV™ Cytovir for the treatment of cytomegalovirus (CMV) infections in patients following allogeneic haematopoietic stem cell transplantation (HSCT). The company is also developing Cytovir™ ADV for the treatment of adenovirus infection in children after HSCT. Cell Medica’s oncology therapeutics are focused on the treatment of virus-associated malignancies. The lead pipeline product, referred to as CMD-003, is comprised of antigen-specific T cells which deliver a highly specific killing function after recognizing cancer cells expressing Epstein-Barr Virus (EBV) antigens. In collaboration with the Centre for Cell and Gene Therapy, Baylor College of Medicine (Houston, Texas) Cell Medica is preparing a phase II trial to investigate the use of CMD-003 for the treatment of EBV associated lymphomas.